

Special Issue

SARS-CoV-2 Infection in Women and Children

Message from the Guest Editor

The SARS-CoV-2 vaccine has been recommended for pregnant women, but survey studies show wildly different results around the world in terms of the willingness to be vaccinated during pregnancy. The cumulative uptake of the SARS-CoV-2 vaccine among pregnant women appears to remain low. A lack of information on the impact of vaccination during pregnancy on fetal safety is one of the most important factors preventing pregnant women from being immunized, thereby preventing herd immunity from being achieved. Vaccinating as many people as possible is crucial if we are to rebuild a normal way of life. Vaccination campaigns are urgently needed to increase confidence in vaccines to help reduce the spread of infection and possible consequences during pregnancy. This Special Issue focuses on the immune response of vaccinated pregnant women, the safety and efficacy of COVID-19 vaccination during pregnancy, and the vaccine's impact on maternal and fetal immune responses. We welcome all types of submissions, including original research, reviews, case reports, etc., for this Special Issue. We look forward to receiving your contributions!

Guest Editor

Dr. Narayanaiah Cheedarla
Department of Pathology and Laboratory Medicine, Emory University
School of Medicine, Atlanta, GA, USA

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/164735

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).